Contera Pharma develops new treatment of movement disorders. Focus is on treatment of L-DOPA induced dyskinesia and tardive dyskinesia.
JM-010 is approved for Phase IIa clinical proof-of-concept studies in L-DOPA induced dyskinesia.
Other projects are in late pre-clinical discovery for Parkinson’s disease, L-DOPA induced dyskinesia and tardive dyskinesia.
Selection of lead development candidates and start of clinical development of several projects is expected in H1.2015.